ClinicalTrials.gg
Biological

Tisagenlecleucel clinical trials

Also written CART-19, CTL019 and KYMRIAH.

studies test it
40
open now
6
in phase 3
5
first study started
2010

How each study uses tisagenlecleucel is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the tisagenlecleucel studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
30 Aug 2017 · Kymriah · BLA 125646 (FDA, Purple Book)
European Union
23 Aug 2018 · Kymriah · EMEA/H/C/004090 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Tisagenlecleucel
17
CTL019 T-cells
4
Tisagenlecleucel-T
3

Brand

KYMRIAH
6

Development codes

CART-19
19
CTL019
16
PEI 19-187
1

Studies by the year they started

40 studies that test it; most in 2016 (7)

Studies that test tisagenlecleucel, by start year
YearStudies
20102
20111
20131
20144
20153
20167
20172
20182
20195
20203
20213
20222
20232
20241
20251
20261

Who runs them

Industry 16 · Other 24

Novartis Pharmaceuticals (14) · University of Pennsylvania (10) · Memorial Sloan Kettering Cancer Center (1) · Masonic Cancer Center, University of Minnesota (1) · Peter MacCallum Cancer Centre, Australia (1) · Sara V. Latorre (1) · Matthew J. Frigault, M.D. (1) · M.D. Anderson Cancer Center (1)

Often tested with

Tested in the same studies.

Axicabtagene ciloleucel (2) · Fludarabine (2) · Cyclophosphamide (2) · Lisocabtagene maraleucel (2) · Ibrutinib (2) · Brexucabtagene autoleucel (1) · Idecabtagene vicleucel (1) · Mosunetuzumab (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 4, 1 in phase 3

Studies that test tisagenlecleucel, phase 3 first.

Studies

Open first, then newest update. How each study uses tisagenlecleucel is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 40

See all 40 studies that test tisagenlecleucel →

Given beside what is tested · 5 — tisagenlecleucel is usual care or a partner of the new treatment

Codes

What other systems call tisagenlecleucel · ClinicalTrials.gg INT000899

  • MeSH (NLM) C000626284tisagenlecleucelConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) Q6C9WHR03OTISAGENLECLEUCELConfirmed FDA, NLM, Wikidata
  • RxNorm 1986438Confirmed FDA, Wikidata
  • Wikidata Q30314624tisagenlecleucelConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C102758TisagenlecleucelOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.